Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$436.6MCash, Jun 2026
19moCash Runway (est.)
+50%Share Count, 1 Year
Follow FDMT by emailGet an email when FDMT pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about FDMT, unsubscribe in one click. Privacy
📣 What FDMT Says Is Next
H2 2027 · “Enrollment completed in June 2026 with N>500 expected to be randomized; topline data expected in H2 2027 o PRISM Phase 1/2 Clinical Trial:”
Company press release, Aug 13, 2026 · SEC filing
Q2 2027 · “Enrollment completed in February 2026 and randomization completed (N=523) in March 2026; topline data expected in Q2 2027”
Company press release, Aug 13, 2026 · SEC filing
in 2027 · ““With topline data from both 4FRONT-1 and 4FRONT-2 in wet AMD expected in 2027, our DME Phase 3 expected to initiate in the third quarter and our Investor Day planned in October, we are well positioned to advance 4D-150 as a potential paradigm-changing backbone therapy for patients with wet AMD and DME.” Recent Highlights and Expected Milestones”
Company press release, Aug 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
FDMT reported $436.6M in cash and short-term investments (as of Jun 30, 2026) and used about $69.6M/quarter in operations, an estimated runway of 18.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:47 · Elevated
Cash runway 19 months +8
ATM program on file since Jun 2024 +15
Shelf registration (S-3, May 2026) +10
Share count +50% in a year +14
Recent financing filings on SEC EDGAR:
May 7, 2026 · Shelf registration, up to $400M · S-3
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for FDMT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.